

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10570849
	Filing Date		2006-03-06
	First Named Inventor	Jamal Tazi	
	Art Unit	1704 1628	
	Examiner Name	Not Yet Assigned R. T. Shiao	
Attorney Docket Number		REGIM 3.3-085	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10570849
Filing Date	2006-03-06
First Named Inventor	Jamal Tazi
Art Unit	4704 1628
Examiner Name	Not Yet Assigned R. T. Shiao
Attorney Docket Number	REGIM 3.3-085

1	SHARP, P.A. (1994). Split genes and RNA splicing. Cell 77, 805-815.	<input type="checkbox"/>
2	MANLEY, J.L. AND TACKE, R. (1996). SR proteins and splicing control. Genes Dev. 10, 1569-1579.	<input type="checkbox"/>
3	GRAVELEY, B.R. Sorting out the complexity of SR protein functions. RNA 2000. 6, 1197-1211.	<input type="checkbox"/>
4	WANG, H.Y. et al., SC35 plays a role in T cell development and alternative splicing of CD45. Mol.Cell 2001. 7, 331-342.	<input type="checkbox"/>
5	EWING, B. AND GREEN, P. Analysis of expressed sequence tags indicates 35,000 human genes. Nat.Genet.2000. 25, 232-234.	<input type="checkbox"/>
6	CARTEGNI, L. et al., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat.Rev. Genet.2002. 3, 285-298.	<input type="checkbox"/>
7	NISSIM-RAFINIA, M. et al., Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. Hum.Mol.Genet.2000. 9, 1771-1778;	<input type="checkbox"/>
8	SAZANI, P. et al., Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol.2002. 20, 1228-1233.	<input type="checkbox"/>
9	CARTEGNI, L. et al., Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat.Struct. Biol.2003. 10, 120-125.	<input type="checkbox"/>
10	ANDREASSI, C. et al., Aclaurubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum.Mol.Genet.2001.10, 2841-2849.	<input type="checkbox"/>
11	LIU, X et al., Partial correction of endogenous DeltaF508 CFTR in human cystic . fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat.Biotechnol. 2002. 20, 47-52.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10570849
Filing Date	2006-03-06
First Named Inventor	Jamal Tazi
Art Unit	1794 1628
Examiner Name	Not Yet Assigned R. T. Shiao
Attorney Docket Number	REGIM 3.3-085

12	UEKAMA, K. et al., Cyclodextrins in drug carrier systems. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 1-40.	<input type="checkbox"/>
13	PROCHIANTZ, A., Getting hydrophilic compounds into cells: lessons from homeopeptides. Curr.Opin.Neurobiol. 1996. 6, 629-634	<input type="checkbox"/>
14	et VIVES, E. et al., A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J.Biol.Chem. 1997. 272, 16010-16017.	<input type="checkbox"/>
15	DOUGLAS, S.J. et al., Nanoparticles in drug delivery. Crit.Rev.Ther.Drug Carrier.Syst. 1987. 3, 233-261 Gregoriadis, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.	<input type="checkbox"/>
16	BLACK, D.L., Mechanisms of Alternative Pre-Messenger RNA Splicing. Annu.Rev.Biochem.2003. 72,291-336.	<input type="checkbox"/>
17	GREGORIADIS, G. et al., Liposomes in drug delivery. Clinical, diagnostic and ophthalmic potential. Drugs 1993. 45, 15-28.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Rei Tsang Shiao/	Date Considered	10/21/10
--------------------	-------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.